MetaCap

Rallybio (RLYB) vs Spero Therapeutics (SPRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rallybio (RLYB) has outperformed Spero Therapeutics (SPRO) over the past year, gaining 208.4% versus a loss of 67.9%. Over five years, RLYB leads with a -85.3% price change compared with -95.1% for SPRO. Rallybio is the larger company by market cap ($43.3 million vs $43.2 million), about 1.0 times the size, while Spero Therapeutics is growing revenue faster (+39.2% vs +34.9%).

Spero Therapeutics converts more of its revenue into profit, with a net margin of 12.8% versus -1046.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RLYB+208.41%SPRO-67.88%
+259%+88%-83%
Nov 21, 20251 yearNov 20, 2026
RLYB-85.73%SPRO-95.50%
+13%-45%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RLYB versus SPRO key metrics
MetricRLYBSPRO
Share price$15.47$0.742
Market cap$43.32M$43.23M
1-day change-0.32%-10.20%
YTD return+181.89%-68.15%
1-year return+208.41%-67.88%
5-year return-85.29%-95.09%
P/E ratio (TTM)3.36—
EPS (TTM)$4.61$-0.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$858.00K$66.80M
Revenue growth (YoY)+34.91%+39.24%
Net income (latest FY)$-8.98M$8.57M
Operating margin-3853.61%9.45%
Net margin-1046.39%12.83%
52-week high$35.15$3.08
52-week low$7.34$0.73
Distance from 52-week high-55.99%-75.91%
Analyst consensus—none
Avg. price target upside—+573.85%
Average volume10.14K530.46K
Shares outstanding2.80M58.26M
Employees725
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RLYB has outperformed SPRO by 276.3 percentage points over the past year.
  • Spero Therapeutics is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -1046.4 cents for Rallybio.

About Rallybio

RLYB stock →

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Spero Therapeutics

SPRO stock →

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

RLYB vs SPRO FAQ

Which is bigger, Rallybio or Spero Therapeutics?

Rallybio (RLYB) is larger, with a market capitalization of $43.32M compared with $43.23M for Spero Therapeutics (SPRO).

Which stock has performed better over the past year, RLYB or SPRO?

RLYB returned +208.41% over the past 12 months, compared with -67.88% for SPRO (price return, excluding dividends). Past performance does not predict future results.

Are Rallybio and Spero Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons